{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Emerging Oral Antiviral Therapies for COVID-19, Early Evidence for the Clinical Nurse Specialist

Activity Steps

Learning Objectives

After completing this continuing education activity you will be able to:

  1. Select indications for the use of molnupiravir and/or PF-07321332-ritonavir.
  2. Specify issues related to the administration of PF-07321332-ritonavir andmolnupiravir.
  3. Identify a country that has authorized the use of molnupiravir.
  4. Explain the actions of PF-07321332-ritonavir.

Learning Outcomes

75% of participants will demonstrate knowledge of PF-07321332-ritonavir and molnupiravir by achieving a minimum score of 70% on the outcomes-based posttest.
Price: $17.95

Credits:

  • ANCC 1.5 CH / 1.5 APH
  • DC - BON 1.5 CH
  • FL - BON 1.5 CH
  • GA - BON 1.5 CH

Lippincott Professional Development is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749. Lippincott Professional Development is also an approved provider of continuing nursing education by the District of Columbia Board of Nursing, Florida Board of Nursing, and Georgia Board of Nursing, #50-1223.

Awarded Advanced Pharmacology Hours







Test Code: CNS0322
Published: Mar/Apr 2022
Expires: 3/7/2025
Required Passing Score: 8/10 (80%)
Authors: Patricia O'Malley, PhD, APRN-CNS
Topics: Antivirals , COVID-19